ALPMY News and Press, Astellas Pharma Inc. ADR From 07/11/23

Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...

Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets PR Newswire TOKYO and EMERYVILLE, Calif. , July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503)...

Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application PR Newswire If approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal cancers TOKYO , J...

Astellas Establishes Open Innovation Hub for Tumor Microenvironment Research with Cutting-Edge Spatial Biology, in Mitsui Fudosan's "MITSUI LINK-Lab KASHIWA-NO-HA 1" PR Newswire TOKYO , June 29, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: N...

Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause PR Newswire Study evaluated 24-week efficacy and safety of Astellas' fezolinetant in women considered unsuitable for hormone therapy TOKYO , June 27, 2023...

2023-06-18 07:05:00 ET Summary San Diego-Shanghai company Cullgen will collaborate with Japan's Astellas Pharma to discover multiple innovative protein degraders in a deal worth up to $1.9 billion. Cholesgen (Shanghai) formed a three-year collaboration with AstraZeneca to develop ...

Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders PR Newswire TOKYO and SAN DIEGO , June 14, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naok...

Gilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD Acute Myeloid Leukemia Patients PR Newswire Data from Phase 3 MORPHO trial selected for press briefing and to be presented as oral session during the 2023 European Hematology Association (EHA) Hy...

Astellas Submits New Drug Application for Zolbetuximab in Japan PR Newswire Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers TOKYO , June 9, 2023 /PRNewswir...

Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 PR Newswire KT430 is a preclinical, next-generation investigational gene therapy to treat X-linked myotubular myopathy (XLMTM) TOKYO and SAN DIEGO , June 8, 2023 /PRNewswire...